Unisys, SurgePays Show Growth Potential; Nkarta Expands into Lupus Treatment with New Partnership
• Unisys (UIS) showed strong customer loyalty and new business growth in 2023, indicating its potential for future expansion.
• SurgePays (SURG) increased revenue by 11% in 2023 and achieved profitability, demonstrating its ability to produce long-term profits.
• Nkarta (NKTX) is expanding its pipeline into autoimmune diseases like lupus nephritis, opening up new areas for growth.
• Nkarta entered a strategic partnership with Lupus Therapeutics to facilitate clinical trial recruitment and access resources.
• Nkarta plans to commence clinical dosing for its NKX019 treatment in lupus nephritis patients in the first half of 2024.